- Seagen to Host Conference Call and Webcast Discussion of Fourth Quarter and Full Year 2020 Financial Results on February 11, 2021
- Seagen to Present at the J.P. Morgan Healthcare Conference
- Alpine Immune Sciences Appoints Natasha Hernday to Board of Directors
- Seagen Announces Positive CHMP Opinion for TUKYSA® (tucatinib) for the Treatment of Patients with Locally Advanced or Metastatic HER2-Positive Breast Cancer
- Seagen Highlights TUKYSA® (tucatinib) Data in Breast Cancer at Virtual 2020 San Antonio Breast Cancer Symposium
- Seagen Announces Multiple ADCETRIS® (brentuximab vedotin) Presentations at the 2020 ASH Annual Meeting
- Seagen Highlights Immuno-Oncology Data from Broad Portfolio During SITC Virtual Annual Meeting 2020
- Seagen Announces Multiple ADCETRIS® (Brentuximab Vedotin) Presentations at the Upcoming ASH Annual Meeting
- Seagen to Host Virtual R&D Day on November 16, 2020
- Seagen Reports Third Quarter 2020 Financial Results
More ▼
Key statistics
On Friday, Seagen Inc (SGEN:NSQ) closed at 182.75, -14.58% below its 52-week high of 213.94, set on Oct 13, 2020.
52-week range
Markit short selling activity
Open | 185.47 |
---|---|
High | 186.96 |
Low | 181.83 |
Bid | 181.27 |
Offer | 189.00 |
Previous close | 185.78 |
Average volume | 827.38k |
---|---|
Shares outstanding | 180.31m |
Free float | 179.25m |
P/E (TTM) | 71.70 |
Market cap | 32.95bn USD |
EPS (TTM) | 2.55 USD |
Data delayed at least 15 minutes, as of Jan 22 2021 21:00 GMT.
More ▼